Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 64.28% is in line with its 5-year average of 59.26%, near the high end of its 5-year range (-207.78%–92.02%).
339.00% above its 12-month average of 14.64%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 72.73%.
GROSS MARGIN
64.28%
GROSS MARGIN AVG TTM
14.64%
GROSS MARGIN AVG 3Y
47.84%
GROSS MARGIN AVG 5Y
59.26%
GROSS MARGIN AVG 10Y
59.94%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+339.00%
CURRENT VS 3Y AVG
+34.38%
CURRENT VS 5Y AVG
+8.48%
CURRENT VS 10Y AVG
+7.23%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.82%
median of 727 covered companies
CURRENT VS SECTOR MEDIAN
+57.47%
vs the sector median at left
Co-Diagnostics, Inc.
Market Cap
$6.69M
Gross Margin
64.28%
TTM Avg
14.64%
3Y Avg
47.84%
5Y Avg
59.26%
Market Cap
$6.74M
Gross Margin
-291.27%
TTM Avg
-237.54%
3Y Avg
-120.88%
5Y Avg
-89.07%
Market Cap
$6.80M
Gross Margin
80.62%
TTM Avg
90.31%
3Y Avg
-419.28%
5Y Avg
-4158.68%
Market Cap
$6.49M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.43M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$7.07M
Gross Margin
54.43%
TTM Avg
58.30%
3Y Avg
57.46%
5Y Avg
45.97%
Market Cap
$7.08M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Co-Diagnostics, Inc. (CODX) | $6.69M | 64.28% | 14.64% | 47.84% | 59.26% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -291.27% | -237.54% | -120.88% | -89.07% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.80M | 80.62% | 90.31% | -419.28% | -4158.68% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.49M | 0.00% | 0.00% | 0.00% | 0.00% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.43M | 0.00% | 0.00% | 0.00% | 0.00% |
| Biomerica, Inc. (BMRA)vs › | $6.54M | 8.09% | 8.76% | 9.29% | 9.67% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.07M | 54.43% | 58.30% | 57.46% | 45.97% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | 0.00% | 0.00% | 0.00% | 0.00% |
| Femasys Inc. (FEMY)vs › | $6.16M | 61.96% | 64.25% | 64.10% | 65.91% |
| KALA BIO, Inc. (KALA)vs › | $7.07M | 0.00% | 0.00% | 8.55% | 24.65% |
Gross Margin
64.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 72.73% |
| 2026-03-31 | -207.78% |
| 2025-12-31 | 46.05% |
| 2025-09-30 | 81.92% |
| 2025-06-30 | 80.29% |
| 2025-03-31 | 57.06% |
| 2024-12-31 | -70.81% |
| 2024-09-30 | 53.61% |
| 2024-06-30 | 92.02% |
| 2024-03-31 | 7.22% |
| 2023-12-31 | 16.52% |
| 2023-09-30 | 89.59% |
| 2023-06-30 | -132.09% |
| 2023-03-31 | 16.57% |
| 2022-12-31 | 63.20% |
| 2022-09-30 | 84.93% |
| 2022-06-30 | 81.78% |
| 2022-03-31 | 85.54% |
| 2021-12-31 | 87.81% |
| 2021-09-30 | 89.00% |
| 2021-06-30 | 90.85% |
| 2021-03-31 | 83.66% |
| 2020-12-31 | 84.11% |
| 2020-09-30 | 73.32% |
| 2020-06-30 | 75.14% |
| 2020-03-31 | 68.89% |
| 2019-12-31 | 51.36% |
| 2019-09-30 | 50.85% |
| 2019-06-30 | 36.97% |
| 2019-03-31 | 86.71% |
| 2018-12-31 | 13.23% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 100.00% |
| 2017-06-30 | 87.75% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 100.00% |
| 2015-12-31 | 100.00% |
